All News
Is MTX Safe in the Elderly? (12.1.2023)
Dr. Jack Cush reviews this past week's news and journal reports from RheumNow.com. Good news is that nearly 99% of adult rheumatology positions matched! But the challenge is that 45% of pediatric fellowship programs and 39% of pediatric rheum slots were unfilled in the 2024 NRMP match.
Read Article
Subcutaneous Biosimilars? (10.27.2023)
Dr. Jack Cush reviews RheumNow's top entries the PMR Campaign, news, journal reports and regulatory actions.
Read Article
Polands disease study (sarcoidosis 78.6K; #AOSD 3294; systemic sclerosis 35.5K) betw 2009-2018. Avg hospitalization was 5.39 days sarcoidosis, 6.22 days scleroderma, & 7.44 days for Still’s (latter decr 11.7 to 5.8, betw 2008-2014) https://t.co/OcNzt7IKC5 https://t.co/uPcbOyizQN
Dr. John Cush RheumNow ( View Tweet)
Chemokine CXCL10 a potential biomarker for ILD in systemic sclerosis (SSc)? Study of 165 SSc pts (41 w/ SSc-ILD) found higher serum CXCL10 in SSc-ILD (126 vs. 78.5 pg/ml). Hi levels incr risk of ILD 2.74-fold. Most CXCL10 from inflammed lung tissues https://t.co/Z8pIAZYaC0 https://t.co/ErRsD9Msn1
Dr. John Cush RheumNow ( View Tweet)
Trajectory of FVC in Systemic sclerosis associated ILD in open label SENSCIS study
Decline in FVC over 52 weeks decreased by 57% on nintedanib
But am I also just seeing a study FVC decline even with nintedanib?
@RheumNow #ACR23 Abs#2594 https://t.co/3h4mhm0ceU
Robert B Chao, MD ( View Tweet)
1st Large real world observational head to head study on tx of Systemic sclerosis - ILD
No difference in treatment effectiveness of FVC change between tocilizumab, rituximab, mycophenolate and cyclophosphamide!
@RheumNow #ACR23 Abs#2596
#ACRBest https://t.co/GaSnZSCcnZ
Robert B Chao, MD ( View Tweet)
Fecal transplant for treatment of GI complications of systemic sclerosis?
No change in those who received transplant...
Overall procedure safe
@RheumNow #ACR23 Abs#2597 https://t.co/TEdeGHuzpi
Robert B Chao, MD ( View Tweet)
Continued interest on CAR-T cells in systemic sclerosis!
6 mo f/up data on 3 pts who received CAR-T cell treatment - stable dz overall
Skin findings improved in all 3 pts
Previous finger ulcerations resolved
Lung function stable in 2 pts, improved in 1
@RheumNow #ACR23 Abs#2598
Robert B Chao, MD ( View Tweet)
#ACR23 Abs 2598 show data on 1st 3 CD19 CAR-T treated SSc pts. Tx well tolerated and dz stabilized off tx x 6 months. Promising, but more data needed for further evaluation. https://t.co/RAKhT6Eygn @rheumnow
Dr. Rachel Tate ( View Tweet)
Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY
Mithu Maheswaranathan, MD ( View Tweet)
🚩Adjunct therapy to treat vasculopathy of MDA5-DM
⭐️Botox heals digital ulcerations and improves Raynaud's (slide 1)
Dr. Katherine Shaw injects Botox for healing recalcitrant ulcerated Gottron's papules (example patient failed nifedipine, sildenafil, pentoxyfylline & while on… https://t.co/4XCvRrzeTL https://t.co/yxUCzS30W1
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
A#L06 #ACR23 @RheumNow
Refractory juv SSc 6m-2y after autolog Stem Cell Tx - 5 patients
HAQ VAS improved 75% (48-99%)
All: mRSS MCID by 6 mo, 87% aver improvement, sustained at 2y
GI: GIT mean 55% improvement, 1 unchanged
FVC stable, DLCO improv >10% in 2, 5-10% in 2
#ACRBest https://t.co/cc6YToVEO5
Eric Dein ( View Tweet)
World's largest jSSc cohort: djSSc pts had more severe dz vs ljSSc pts. DjSSc pts w/ more cutaneous, vascular, MSK involvement vs ljSSc pts w/ more cardiac involvement. No significant differences in ILD, PAH, GI involvement. #ACR23 Abs #1623 https://t.co/czAH0hpY2a @rheumnow https://t.co/RcfAJORXY3
Dr. Rachel Tate ( View Tweet)
#ACR23
Scleroderma renal Crisis (SRC)
May precede skin involvement also.
RISK FACTORS
• Early diffuse skin disease
- 2-3 years from SSc onset, median 8 months
• Anti-RNA polymerase III (60%)
• Use of corticosteroids
- >15 mg/d or low doses for longer time https://t.co/RSIxEXLdX7
Aditya Burje AdityaBurje ( View Tweet)
#ACR23 #ReviewCourse - By Dr. Francesco Boin. Systemic Sclerosis Screening for Organ Involvement. This slide is a true "take home slide" @ACRheum #ACRambassador https://t.co/4FVYWJjHyV
Anne Troldborg ( View Tweet)
💡Screen pts with Ssc for ILD with HRCT at diagnosis.
💡“MCTD” may meet criteria for Ssc dont look away at the positive U1RNP!
💡Kidney biopsy in SRC =Time is of the essence.
💡Cardiac involvement is 2nd cause of mortality screen with echo annually. @fboinMD #ACR23 @RheumNow https://t.co/yp3yjqqeQv
Adela Castro AdelaCastro222 ( View Tweet)
Assessment of organ involvement in scleroderma by Boin F, a great example of great clearly presented slides #ACR23 @RheumNow https://t.co/zMwY1NGpYI
Dr. Antoni Chan ( View Tweet)
The message about scleroderma we need to keep on saying to those outside of rheumatology:
you can get severe organ involvement in both limited & diffuse SSc
survival is dictated by organ involvement
screening is needed regardless!
Francesco Boin #ACR23 Review Course @RheumNow https://t.co/otUPjWNVoo
David Liew drdavidliew ( View Tweet)
Genetic links for Raynauds Phen (RP): Large GWAS study of 5147 RP cases in the UK Biobank cohort shows 2 robust and strong (p < 4.8 × 10−13) novel loci A) ADRA2A (rs7090046, OR per allele: 1.26) & B) IRX1 (rs12653958, OR: 1.17) as candidate causal genes https://t.co/Jho4CKmITU https://t.co/Gstxdejpc0
Dr. John Cush RheumNow ( View Tweet)
Genetic links for Raynauds Phen (RP): Large GWAS study of 5147 RP cases in the UK Biobank cohort shows 2 robust and strong (p < 4.8 × 10−13) novel loci A) ADRA2A (rs7090046, OR per allele: 1.26) & B) IRX1 (rs12653958, OR: 1.17) as candidate causal genes https://t.co/W6F736uskO https://t.co/u1IZnIy7wg
Dr. John Cush RheumNow ( View Tweet)
